Autoimmune disease companies develop therapies, diagnostics and research technologies for conditions in which the immune system attacks the body’s own cells and tissues. Their work spans disease detection, immune modulation and the development of more targeted treatments.
This category includes companies working on:
Browse 68 UK autoimmune disease companies below.
Global biopharmaceutical company developing therapies for serious diseases
AbbVie is a global research-based biopharmaceutical company focused on the discovery, development and commercialisation of medicines across immunology, oncology, neuroscience and aesthetics. Its portfolio includes treatments for autoimmune diseases, haematological cancers, neurological conditions and women's health.…
Antigenic immunomodulation therapies targeting autoimmune disease
Phaim Pharma is a biotech company developing disease-modifying therapeutics for autoimmune conditions using its proprietary platform. The platform is designed to reset the immune system by reintroducing disease-specific antigenic epitopes, suppressing the autoaggressive T cell responses that underlie conditions such…
Clinical-stage bispecific antibody therapies for cancer and blood disease
NovalGen is a clinical-stage biotechnology company developing multi-specific biologics for oncology, haematological malignancies, and autoimmune diseases. Its proprietary platform embeds a feedback mechanism into therapeutic biologics that deactivates the drug in response to excessive immune activation, aiming to…
Intranasal anti-CD3 immunotherapy for neuroinflammatory diseases
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing immunomodulatory therapies for neurological and inflammatory diseases. Its lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody designed to modulate T-cell activity through nasal administration. The 48-patient…
Antigen modulation therapies for cancer and autoimmune disease
Grey Wolf Therapeutics is a clinical-stage biotechnology company developing small molecule inhibitors of endoplasmic reticulum aminopeptidases (ERAP1 and ERAP2) to modulate antigen presentation on cell surfaces. In oncology, this approach enhances tumour visibility to the immune system; in autoimmunity, it aims to…
Virus-like particle therapeutics for chronic inflammatory skin conditions
Glen Clova Scientific is a biotechnology company developing active biologic drugs for chronic inflammatory and autoimmune disorders, with an initial focus on immuno-dermatology. Its proprietary virus-like particle platform is designed to induce targeted immune responses against self-produced proteins that drive…
CAR-T and bispecific antibody therapies for blood cancers
Hemogenyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for haematological malignancies and autoimmune diseases. Its lead asset, HG-CT-1, is a third-generation anti-FLT3 CAR-T cell therapy for relapsed and refractory acute myeloid leukaemia, currently in a Phase 1…
Genomic risk prediction platform for preventive healthcare and drug discovery
Genomics is a data science company that uses large-scale human genetic data to power precision healthcare and drug discovery. Its proprietary platform links millions of genetic variants to thousands of biological measurements and disease outcomes, generating polygenic risk scores that enable earlier identification of…
Inorganic nanoscale immune modulators for infection, cancer and autoimmunity
Iuvantium is a biotechnology company developing therapeutics and vaccines based on inorganic nanoscale materials that modulate the immune system. The company uses tailored inorganic probes to study how the immune system responds, builds a computational model of immune behaviour, and designs programmable immune…
Small molecule remyelination therapeutics for neurological diseases
Pheno Therapeutics is a Scottish clinical-stage biotechnology company developing small molecule therapeutics that promote remyelination by boosting the function of oligodendrocytes in the central nervous system. Its lead programme PTD802, a selective GPR17 antagonist licensed from UCB, received MHRA clinical trial…
In vivo immune cell reprogramming for autoimmune and inflammatory disease
Flip Therapeutics is a biotechnology company developing in vivo immune cell engineering therapies for chronic autoimmune and inflammatory diseases, including multiple sclerosis, type 1 diabetes and inflammatory bowel disease. The company reprograms pathogenic T cells into homeostatic, anti-inflammatory cells directly…
Small molecule drug discovery platform focused on immuno-inflammation
C4X Discovery (C4XD) is a UK drug discovery company developing small molecule drug candidates using its proprietary computational and structural chemistry platform. It applies enhanced candidate molecule design and patient stratification capabilities to generate drug candidates across immuno-inflammatory disease…
Engineered T-regulatory cell therapies for immune-mediated diseases
Quell Therapeutics is a clinical-stage UK biotech developing engineered T-regulatory (Treg) cell therapies for immune-mediated diseases, using its proprietary technology to engineer Tregs with enhanced persistence and potency. Its lead candidate QEL-001 is in the Phase 1/2 LIBERATE trial for liver transplant…
AI-powered immune profiling platform for precision medicine
IMU Biosciences is a biotechnology company coupling high-resolution, systems-level immune profiling with proprietary AI analytics to build a detailed atlas of the human immune system across health and disease. Its platform can identify and analyse over 2,000 immune cell subsets from blood samples, generating…
3D multi-omics platform for genetically validated drug target discovery
Enhanced Genomics is a biotechnology company developing a proprietary 3D multi-omics platform that maps genome-wide chromatin interactions to identify genetically validated drug targets for common diseases. Using patented technology integrated with a human cell type-specific multi-omics atlas, the platform links…
TCR bispecific immunotherapies for cancer and infectious disease
Immunocore is a commercial-stage biopharma developing T cell receptor bispecific immunotherapies. Its lead product tebentafusp received FDA approval in 2022 for metastatic uveal melanoma and generated $400 million in revenue in 2025. Three Phase 3 trials are enrolling across melanoma indications, with topline data…
Antibody therapies depleting pathogenic T cells for autoimmune disease cure
Re-Aim Therapeutics is a biotechnology company developing antibody-based therapies designed to achieve functional cures for T cell-mediated autoimmune diseases. The company's approach selectively depletes pathogenic T cell subsets that drive chronic inflammation, using precise targeting of disease-relevant membrane…
Clinical-stage peptide therapeutics for autoimmune and infectious disease
ImmuPharma is a clinical-stage biopharmaceutical company developing peptide-based therapeutics and precision diagnostics for autoimmune disease, infectious disease and metabolic disorders. Its lead candidate, a first-in-class immunormalizer for lupus, has completed a Phase III pivotal trial, aiming to restore normal…
AI analysis of brain MRI for neurological diagnosis and prognosis
Ainostics is a medical artificial intelligence company developing software that analyses brain scans and clinical data to support the diagnosis and prognosis of neurological disorders. Its platform derives detailed measures of brain tissue structure from routine MRI and compares them with healthy populations to detect…
Preclinical immunology CRO for drug discovery programmes
Nexus BioQuest is a contract research organisation specialising in preclinical immunology services for the biotechnology and pharmaceutical industries. The company offers bespoke assay development and in vitro screening across immuno-oncology, autoimmunity, inflammation, and neuroinflammation, including cytokine…